Lineage Cell Therapeutics opens new California R&D facility and expands Israel manufacturing site
Last year, Roche and Genentech paid $50 million for licensing rights to Lineage Cell Therapeutics’ OpRegen program, a cell therapy that looks to regenerate healthy versions of retinal pigment epithelial cells in patients’ eyes.
Now the biotech is growing its physical presence with a new facility in the US and an expansion in Israel.
Lineage has opened the doors to a 12,000-square-foot R&D facility in Carlsbad, CA, and announced an expansion to its GMP manufacturing facility in Jerusalem. The expansion in Israel will allow for the development of more large-scale manufacturing processes and the continued supply of materials necessary for the Phase I/II of OpRegen.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.